Autologous Tumor-Infiltrating Lymphocyte (GT307 Injection ) for Treatment of Patients with Solid Tumours
This study is a single arm, open design aimed at evaluating the safety and tolerability of Autologous Tumor-Infiltrating Lymphocyte (GT307 injection ) for treatment of patients with solid tumours,while evaluating pharmacokinetic characteristics and efficacy assessment to determine the optimal biological dose (OBD).
Solid Tumor, Adult
BIOLOGICAL: GT307 injection
Incidence and severity of adcersed events per CTCAE 5.0, To characterize the safety profile of autologous TIL injectionï¼ˆGT307) in patients with relapsed/metastatic advanced solid tumor as measured by the incidence and severity of adcersed events per CTCAE 5.0, 3 years
Objective response rate, To evaluate efficacy parameters such Objective Response Rate (ORR) per RECIST 1.1, as assessed by the Investigator, 3 years
This study is a single arm, open design aimed at evaluating the safety and tolerability of Autologous Tumor-Infiltrating Lymphocyte (GT307 injection ) for treatment of patients with solid tumours,while evaluating pharmacokinetic characteristics and efficacy assessment to determine the optimal biological dose (OBD).